Annual Report 2020 Contents
Total Page:16
File Type:pdf, Size:1020Kb
ANNUAL REPORT 2020 CONTENTS Corporate Information 2 Definition 3 Company Profile 5 CEO’s Statement 6 Performance Overview 9 Management Discussion 13 and Analysis Corporate Governance Report 57 Biography of Directors 71 Directors’ Report 79 Environmental, Social and 111 Governance Report Independent Auditor’s Report 153 Consolidated Statement of 158 Profit or Loss Consolidated Statement of 159 Comprehensive Income Consolidated Statement of 160 Financial Position Consolidated Statement 162 of Changes in Equity Consolidated Statement of Cash Flows 164 Notes to Financial Statements 167 CORPORATE INFORMATION BOARD OF NOMINATION HEAD OFFICE AND DIRECTORS COMMITTEE PRINCIPAL PLACE OF BUSINESS IN CHINA Chairman and Mr. Zhang Yichen (Chairman) Vice-chairman Mr. Chow Siu Lui 4th, 5th and 13th Floor Mr. Zhang Yichen (Chairman) Mr. Liao Xinbo West Wing of Hademen Plaza Ms. Peng Jiahong 8-1 Chongwenmenwai Street (Vice-chairwoman) STRATEGY Dongcheng District COMMITTEE Beijing, China Executive Directors Ms. Peng Jiahong (Chairwoman) Ms. Peng Jiahong SHARE REGISTRAR Mr. Zhang Yichen (Chief Executive Officer) Ms. Liu Kun Computershare Hong Kong Mr. Yu Gang Investor Services Limited Non-executive RISK CONTROL Shops 1712-1716, 17th Floor Directors COMMITTEE Hopewell Centre 183 Queen’s Road East Mr. Zhang Yichen Mr. Su Guang (Chairman)* Wan Chai Ms. Liu Kun Mr. Liu Zhiyong Hong Kong Mr. Liu Zhiyong Ms. Peng Jiahong Mr. Liu Xiaoping* AUDITORS Mr. Su Guang* COMPANY Independent Non- SECRETARY Ernst & Young (Public Interest Entity Auditor executive Directors Ms. Ng Wai Kam registered in accordance with Mr. Li Yinquan the Financial Reporting Council Mr. Chow Siu Lui AUTHORISED Ordinance) Mr. Han Demin REPRESENTATIVES Mr. Liao Xinbo Ms. Peng Jiahong LEGAL ADVISER Ms. Ng Wai Kam AUDIT COMMITTEE Wilson Sonsini Goodrich & Rosati Mr. Li Yinquan (Chairman) REGISTERED OFFICE Mr. Liu Xiaoping* PRINCIPAL BANKERS Mr. Chow Siu Lui Room 702, Fairmont House Bank of Communications, Beijing 8 Cotton Tree Drive Fuwai Subbranch REMUNERATION Central Bank of China (Hong Kong) Limited COMMITTEE Hong Kong Mr. Chow Siu Lui (Chairman) COMPANY’S Mr. Liu Zhiyong WEBSITE Mr. Han Demin www.umcare.cn STOCK CODE 2666 * Resigned with effect from 6 March 2021 2 Genertec Universal Medical Group Company Limited DEFINITION “2021 AGM” the annual general meeting of the Company to be held on 8 June 2021 “Ansteel Group Hospital” Ansteel Group General Hospital (鞍鋼集團公司總醫院) “Articles” the articles of association of the Company “Audit Committee” the audit committee of the Board “Board” or “Board of the board of Directors Directors” “CG Code” the “Corporate Governance Code” contained in Appendix 14 to the Listing Rules “CITIC Capital” CITIC Capital Holdings Limited “CITIC Capital (Tianjin)” CITIC Capital Equity Investment (Tianjin) Corporation Limited (中信資本股權 投資(天津)股份有限公司) “CITIC CPL” CITIC Capital Partners Limited “CNTIC” China National Technical Import & Export Corporation (中國技術進出口總公 司), a company incorporated in the PRC and a wholly-owned subsidiary of GT-PRC “Companies Ordinance” the Companies Ordinance (Chapter 622 of the Laws of Hong Kong, which has become effective from 3 March 2014), as amended, supplemented or otherwise modified from time to time “Company” or “Universal Genertec Universal Medical Group Company Limited (通用環球醫療集 Medical” 團有限公司) (formerly known as Universal Medical Financial & Technical Advisory Services Company Limited (環球醫療金融 與技術咨詢服務有限公司), Universal Medical Services & Health Management Company Limited (環球醫 療服務有限公司) and Universal International Leasing Co., Limited (環球國際 租賃有限公司)), a company incorporated with limited liability under the laws of Hong Kong on 19 April 2012 “CR State Asset” China Railway State Asset Management Co., Ltd. (中鐵國資資產管理有限公 司) “CULC” China Universal Leasing Co., Ltd. (中國環球租賃有限公司), a wholly foreign- owned enterprise incorporated in China on 1 November 1984 and a wholly- owned subsidiary of the Company “CVA” cerebral vascular accident “DIP” Big Data Diagnosis – Intervention Packet (基於大數據的病種) “Director(s)” the director(s) of the Company “DRG” Diagnosis Related Groups (按疾病診斷相關分組) “Evergreen” Evergreen021 Co., Ltd, a company incorporated under the laws of the British Virgin Islands on 14 August 2014 with limited liability “Existing Minmetals Minmetals Assets Management Company Limited (五礦資產經營管理有 Investors” 限公司), China MCC 5 Group Co., Ltd. (中國五冶集團有限公司), China MCC 19 Group Co., Ltd. (中國十九冶集團有限公司), China MCC 17 Group Co., Ltd. (中國十七冶集團有限公司) and Minmetals (Handan) Real Estate Management Company Limited (五礦(邯鄲)房產管理有限公司) “Group”, “we” or “us” the Company and its subsidiaries 2020 Annual Report 3 DEFINITION “GT-HK” Genertec Hong Kong International Capital Limited (通用技術集團香港國際 資本有限公司), a company incorporated under the laws of Hong Kong on 24 March 1994 with limited liability, an indirect wholly-owned subsidiary of GT-PRC, and one of the controlling shareholders of the Company “GT-PRC” China General Technology (Group) Holding Company Limited (中國通用技術 (集團)控股有限責任公司), which is a state-owned enterprise under the direct administration of the PRC central government, the controlling shareholder of the Company “HKD” Hong Kong dollars, the lawful currency of Hong Kong “Hong Kong” the Hong Kong Special Administrative Region of the People’s Republic of China “Hospital Investment Co., Genertec Universal Hospital Investment & Management (Tianjin) Co., Ltd. (通 Ltd.” 用環球醫院投資管理(天津)有限公司), previously known as Wiseman Hospital Investment Management (Tianjin) Co., Ltd. (融慧濟民醫院投資管理(天津)有 限公司), a wholly-owned subsidiary of the Company established in the PRC in 2015 “Listing Rules” the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time “Model Code” the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix 10 to the Listing Rules “New Minmetals Investors” Beijing Haide Ruixiang Assets Management Co., Ltd. (北京海德瑞祥資產管 理有限公司) and Beijing Dongxing Metallurgical New-Tech & Development Corporation. (北京東星冶金新技術開發有限公司) “Nomination Committee” the nomination committee of the Board “PRC” or “China” The People’s Republic of China, for the purpose of this report, excluding Hong Kong, Macau and Taiwan “Prospectus” the prospectus issued by the Company on 24 June 2015 “Remuneration Committee” the remuneration committee of the Board “Risk Control Committee” the risk control committee of the Board “RMB” Renminbi, the lawful currency of the PRC “Securities Dealing Code” the Company’s own code of conduct regarding directors’ and employees’ dealings in the Company’s securities “SFO” Hong Kong Securities and Futures Ordinance “Share(s)” ordinary share(s) in the share capital of the Company “Shareholder(s)” holder(s) of Shares “Share Option Scheme” the share option scheme adopted by the Company on 31 December 2019 “SOE” state-owned enterprise “Stock Exchange” The Stock Exchange of Hong Kong Limited “Strategy Committee” the strategy committee of the Board “USD” United States dollars, the lawful currency of the United States 4 Genertec Universal Medical Group Company Limited COMPANY PROFILE Genertec Universal Medical Group Company Limited (通用環球醫療集團有限公司) (“Universal Medical”) is a listed company under China General Technology (Group) Holding Company Limited (中國通用技術(集 團)控股有限責任公司), a backbone state-owned enterprise under direct administration of the PRC central government, and a conglomerate controlled by the central enterprise and focusing on healthcare industry. Universal Medical was listed on the Main Board of the Stock Exchange in July 2015, stock code: 2666. With the operation center located in Beijing, we have over 50 medical institutions distributed in 11 provinces and municipalities including Shaanxi, Shanxi, Anhui, Hebei, Sichuan and Liaoning, with a capacity of over 15,000 beds in total. We have been fully engaged in China’s fast-growing medical and healthcare industry for years. Leveraging core competencies in modern managerial idea, professional talent team, quality medical resources, diversified financial strength as well as inclusive and enterprising corporate culture, we strive to build up a trustworthy healthcare conglomerate focusing on medical services and supported by financial services so as to gradually build a shared and win-win healthcare industrial ecosystem. Universal Medical shoulders the mission as a central enterprise to actively respond to the “Healthy China” strategy and strive to contribute to China’s healthcare undertakings. 2020 Annual Report 5 CEO’S STATEMENT CEO’S STATEMENT Dear shareholders, The year of 2020 is destined to be an extraordinary year in human history, as the COVID-19 epidemic swept up the world and brought unprecedented challenges to the economic order as well as the public health security of all countries. The transformation unseen in a century has been accelerated and the world is entering into a period of turbulence and transformation. Facing the complex and grave external situation, Universal Medical forged ahead against all odds and made new progress despite the challenges. Focusing on the goal of building a trustworthy healthcare conglomerate, it has always implemented it with focuses on serving the country’s development strategies and achieving high-quality development. We overcame various unfavorable conditions and forged ahead with determination to steadily develop our financial business and further promote our healthcare business. In this way, we built the core capabilities of the healthcare conglomerate, further strengthened the foundation